{"id":"NCT03908970","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome","officialTitle":"A Multicenter, Randomized, Double-blind, Vehicle Controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 1% OPA-15406 Ointment to the Vehicle in Adult Patients With Atopic Dermatitis (Phase 3 Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-25","primaryCompletion":"2019-12-28","completion":"2019-12-28","firstPosted":"2019-04-09","resultsPosted":"2021-01-25","lastUpdate":"2021-01-25"},"enrollment":364,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"1% OPA-15406","otherNames":[]},{"type":"DRUG","name":"Placebos","otherNames":[]}],"arms":[{"label":"1% OPA-15406","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in adult patients with AD.","primaryOutcome":{"measure":"Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity","timeFrame":"At Week 4","effectByArm":[{"arm":"1% OPA-15406","deltaMin":38.46,"sd":null},{"arm":"Placebo","deltaMin":12.64,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":182},"commonTop":["Dermatitis atopic"]}}